ReviewCancer control : journal of the Moffitt Cancer Center
Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma.
Review in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Efficacy and safety of molecular targeted therapies in nasopharyngeal carcinoma: a network meta-analysis.BMC cancer · 2025Pooled it
- Global trends in research of nasopharyngeal carcinoma: a bibliometric and visualization analysis.Frontiers in oncology · 2024Pooled it
- Treatment Protocols in the Efficacy and Safety of Anti-EGFR Medicines in Combination with Standard Therapy for Patients with Nasopharyngeal Cancer: A Meta-Analysis.BioMed research international · 2023Pooled it
- Paired Agent Imaging to Evaluate the Improvement of Affinity-Matured Nimotuzumab K4 and K5 Variants as EGFR-Detecting Optical Imaging Agents.Molecular pharmaceutics · 2026Article
- Novel Therapeutic Development for Nasopharyngeal Carcinoma.Current oncology (Toronto, Ont.) · 2025Review
- DDAH1 Promotes Cisplatin Chemoresistance in Patients with Locally Advanced Nasopharyngeal Carcinoma via the EGFR-JAK2-STAT3 Pathway.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Machine learning for predicting distant metastasis in nasopharyngeal carcinoma patients.Frontiers in immunology · 2025Article
- Prognostic Significance of Cervical Lymph Node Biopsy in Nasopharyngeal Carcinoma Patients: A Retrospective Analysis.Cancer management and research · 2025Article
- Haplo-hematopoietic stem cell transplantation and immunoradiotherapy for severe aplastic anemia complicated with nasopharyngeal carcinoma: A case report.Open life sciences · 2025Article
- Development of Traditional Chinese Medicine in combination with EGFR Inhibitors against Cancer.Journal of Cancer · 2025Review
- Article
- Addition of nimotuzumab to concurrent chemoradiotherapy after induction chemotherapy improves outcomes of patients with locally advanced nasopharyngeal carcinoma.Frontiers in pharmacology · 2024Article
- Anti-Infection of Nasopharyngeal Carcinoma Combined with Non-Tuberculous Mycobacteria: A Case Report and Literature Review.Infection and drug resistance · 2024Article
- miR-199a/214 cluster enhances prostate cancer sensitiveness to nimotuzumab via targeting TBL1XR1.The Kaohsiung journal of medical sciences · 2023Article
- Article
- Review
- Cetuximab or nimotuzumab in combination with chemotherapy for treating recurrent/metastatic nasopharyngeal carcinoma: A meta‑analysis and systemic review.Oncology letters · 2023Article
- PET/CT standardized uptake value and EGFR expression predicts treatment failure in nasopharyngeal carcinoma.Radiation oncology (London, England) · 2023Article
- EBV-positive large-cell and small-cell neuroendocrine carcinoma of the nasopharynx: A case report and review of the literature.Oncology letters · 2022Article
- The anticancer effect of EGFR-targeting artificial microRNA controlled by SLPI promoter in nasopharyngeal carcinoma.Journal of clinical laboratory analysis · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidermal growth factor receptor (EGFR) is highly expressed in most of Nasopharyngeal carcinoma (NPC) samples and is associated with poor outcomes. Therefore, targeting EGFR may be a promising strategy to improve patient prognosis. Nimotuzumab is a humanized anti-EGFR monoclonal antibody. Recently, accumulating evidence has demonstrated that combination nimotuzumab and induction chemotherapy, radiotherapy, or concurrent chemoradiotherapy confer benefits for patients with NPC. Moreover, the side effects of such regimes are tolerable. In this review, we focus on the current data of nimotuzumab in clinical trials in the treatment of NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.